Haemonetics (HAE) Cash & Equivalents (2009 - 2026)

Haemonetics has reported Cash & Equivalents for 18 years, with the latest figure at $223.4 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 23.73% year-over-year to $223.4 million in Q2 2026; TTM through Jun 2026 was $223.4 million, a 23.73% decrease from a year earlier, with the FY2026 full-year figure at $245.4 million, down 19.99% from the prior year.
• Cash & Equivalents was $223.4 million for Q2 2026 at Haemonetics, down from $245.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $363.4 million in Q4 2025, with the low at $178.8 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $271.8 million, with a median of $284.5 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 37.15% in 2024, then surged 71.57% in 2025.
• Over 5 years, Cash & Equivalents stood at $224.0 million in 2022, then decreased by 13.4% to $194.0 million in 2023, then surged by 65.4% to $320.8 million in 2024, then gained by 13.25% to $363.4 million in 2025, then sank by 38.52% to $223.4 million in 2026.
• The last three Cash & Equivalents figures came in at $223.4 million (Q2 2026), $245.4 million (Q1 2026), and $363.4 million (Q4 2025), per Business Quant data.